Related Experiment Video
Updated: May 14, 2026
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Effects of HPgV-1 Infections on Clinical Outcomes in Patients With Acute Lymphoblastic Leukemia After Allogeneic
Zhanjia Li1, Yuhang Li2, Shuiping Chen1
1Department of Laboratory Medicine, 5th Medical Center of Chinese PLA General Hospital, Beijing, China.
Background:
Although the human pegivirus 1 (HPgV-1) infection is highly prevalent in immunocompromised populations, the effects of the infections on clinical outcomes in leukemia patients after stem cell transplantation (HSCT) are unclear.
Methods:
A total of 16 acute lymphoblastic leukemia (ALL) patients with allogeneic HSCT (allo-HSCT) were included in this matched case-control study and 1-year survival outcomes were evaluated.
Results:
One-year survival analysis showed that HPgV-1 infections could significantly decrease overall survival (OS), but non-significant differences in acute graft-versus-host disease (GVHD) grade III-IV, severe chronic GVHD, leukemia relapse, progression-free survival (PFS), and GVHD-free relapse-free survival (GRFS) were observed when compared with those without HPgV-1 infections. The infections also did not significantly impact the immune reconstitution.
Conclusion:
Our study suggests that HPgV-1 infections can decrease overall survivals in ALL patients at 1 year after allo-HSCT, which provides a foundation for larger, prospective, case-control studies to evaluate the overall effects of HPgV-1 infection on survival outcomes of leukemia patients with allo-HSCT.
